Palexia

Active Ingredient:: Tapentadol Hydrochloride
Origin:: EU

Palexia (Tapentadol Hydrochloride)

International sale not permitted. Listed for the domestic market and B2B only.

Tapentadol hydrochloride, the active ingredient in Palexia, is an opioid analgesic presented as a tablet for oral use. It is indicated for the management of moderate to severe acute pain in adults. GNH India supplies Palexia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH India supplies Palexia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Grünenthal Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Tapentadol hydrochloride is used in the management of pain within the nociceptive and neuropathic pathways.

Acute postoperative pain: provides effective relief when non‑opioid analgesics are insufficient.
Chronic musculoskeletal pain: helps reduce pain intensity in conditions such as osteoarthritis.
Cancer‑related pain: contributes to overall pain control as part of a multimodal regimen.
Neuropathic pain associated with diabetic peripheral neuropathy: alleviates burning and shooting sensations.
Severe trauma pain: offers strong analgesia during the acute phase of injury.

How It Works

Tapentadol hydrochloride exerts analgesia through a dual mechanism: it is a µ‑opioid receptor agonist that activates central opioid pathways, and it inhibits the reuptake of norepinephrine, enhancing descending inhibitory pain signals. This combined action reduces the perception of pain at both spinal and supraspinal levels.

Side Effects

Tapentadol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

Nausea
Dizziness
Constipation
Headache
Somnolence
Dry mouth

Serious or Rare Side Effects

Respiratory depression
Seizures
Severe hypotension
Serotonin syndrome
Allergic reactions (rash, angioedema)
Dependence or abuse potential

Precautions & Warnings

When prescribing Tapentadol, clinicians should consider several safety aspects.

Assess pain severity: ensure the drug is appropriate for moderate to severe pain.
Review medical history: check for respiratory disorders, head injury, or substance abuse.
Monitor for sedation: advise patients about activities requiring alertness.
Avoid abrupt discontinuation: taper dose to prevent withdrawal.
Concomitant CNS depressants: use with caution due to additive effects.
Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Tapentadol can interact with several medication classes, requiring careful management.

Major Interactions (Avoid)

Other opioids or strong CNS depressants: risk of profound respiratory depression.
MAO inhibitors: may precipitate hypertensive crisis or serotonin syndrome.
Serotonergic agents (SSRIs, SNRIs, tramadol): increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

Benzodiazepines: enhanced sedation and respiratory effects.
Alcohol: additive CNS depression.
CYP2D6 inhibitors (e.g., fluoxetine): may alter tapentadol metabolism.
Antihypertensives: possible additive hypotensive effect.
Diuretics: may increase risk of orthostatic hypotension.

Frequently Asked Questions

Palexia contains tapentadol hydrochloride and is prescribed to treat moderate to severe pain, including acute postoperative pain, cancer‑related pain, and certain types of chronic musculoskeletal pain when other analgesics are insufficient.

Tapentadol provides pain relief through two mechanisms: it activates µ‑opioid receptors in the central nervous system and inhibits the reuptake of norepinephrine, which together enhance the body’s natural pain‑inhibiting pathways.

The appropriate dose of Palexia is determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, and overall health status. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Tapentadol is classified as a pregnancy‑category C medication, indicating that risk cannot be ruled out. It is generally not recommended for use during pregnancy or while breastfeeding unless the potential benefit justifies the potential risk to the infant.

To order Palexia, submit an enquiry on the product page at gnhindia.com, providing the required quantity and institutional credentials. GNH India works with hospitals, pharmacies and procurement teams worldwide, responding with pricing, availability, shipping details and any necessary import documentation.

Compared with traditional opioids such as morphine, tapentadol has a dual mechanism that may provide effective analgesia with a potentially lower incidence of some opioid‑related side effects, though it still carries risks of dependence and respiratory depression.

Palexia tablets should be stored at temperatures below 25 °C, in their original packaging, protected from moisture and direct sunlight to maintain potency and stability.

Palexia is supplied as oral tablets and should be taken by mouth with or without food, according to the prescribing clinician’s directions. Swallow the tablet whole; do not crush or chew unless specifically instructed.

The most serious risks include respiratory depression, severe hypotension, seizures, serotonin syndrome when combined with serotonergic drugs, and the potential for dependence, abuse, or withdrawal upon abrupt discontinuation.

Palexix should not be used by individuals with known hypersensitivity to tapentacid or any opioid, those with severe respiratory depression, acute or severe asthma, or patients currently taking MAO inhibitors. A thorough medical assessment is required before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 11 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.